(12) Oversettelse av europeisk patentskrift (11) NO/EP 2125711 B1 (19) NO NORGE (51) Int Cl. C07C 321/20 (2006.01) A61K 31/216 (2006.01) A61K 31/421 (2006.01) A61K 31/4402 (2006.01) A61K 31/495 (2006.01) A61P 1/00 (2006.01) C07C 271/26 (2006.01) C07C 309/70 (2006.01) C07C 317/24 (2006.01) C07C 327/28 (2006.01) m.flere Patentstyret (21) Oversettelse publisert 2014.03.31 (80) Dato for Den Europeiske Patentmyndighets publisering av det meddelte patentet 2013.11.06 (86) Europeisk søknadsnr 08724206.1 (86) Europeisk innleveringsdag 2008.03.07 (87) Den europeiske søknadens Publiseringsdato 2009.12.02 (30) Prioritet 2007.03.08, US, 893681 P 2007.03.08, US, 893683 P 2007.03.08, US, 893689 P 2007.03.08, US, 893695 P (84) Utpekte stater AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MT NL NO PL PT RO SE SI SK TR (73) Innehaver Albireo Ab, Legal Department, 151 85 Södertälje, Sverige (72) Oppfinner BROO, Anders, AstraZeneca R & D Mölndal, S-431 83 Mölndal, Sverige GOTTFRIES, Johan, AstraZeneca R & D Mölndal, S-431 83 Mölndal, Sverige KOSSENJANS, Michael, AstraZeneca R & D Mölndal, S-431 83 Mölndal, Sverige LANNA, Li, AstraZeneca R & D Mölndal, S-431 83 Mölndal, Sverige LINDSTEDT-ALSTERMARK, Eva-Lotte, AstraZeneca R & D Mölndal, S-431 83 Mölndal, Sverige NILSSON, Kristina A, AstraZeneca R & D Mölndal, S-431 83 Mölndal, Sverige OHLSSON, Bengt, AstraZeneca R & D Mölndal, S-431 83 Mölndal, Sverige THORSTENSSON, Maria, AstraZeneca R & D Mölndal, S-431 83 Mölndal, Sverige BOIJE, Maria, AstraZeneca R & D Mölndal, S-431 83 Mölndal, SE-Sverige (74) Fullmektig Zacco Norway AS, Postboks 2003 Vika, 0125 OSLO, Norge (54) Benevnelse 3-FENYLPROPlONSYREDERIVATER OG DERES ANVENDELSE I BEHANDLING AV INFLAMMATORISK TARMSYKDOM (56) Anførte publikasjoner EP-A1-1 375 472 EP-A1-1 607 103 US-B1-6 506 797 US-B1-6 884 821 WO-A1-2005/105724 WO-A1-2005/105764 COX: DRUG METABOLIM AND DISPOSITION, vol. 28, no. 7, 31 December 2000 (2000-12-31), pages 772-780,NASSAR: DRUG DISCOVERY TODAY, vol. 9, no. 23, 31 December 2004 (2004-12-31), pages 1020-1028,NOMURA M. ET AL.: 'Design, synthesis, and evaluation of substituted phyenylpropanoic acid derivatives as human peroxisome proliferator activated receptor activators. Discovery of potent and human peroxisome proliferator activated receptor alfa subtype-selective activators' J. MED. CHEM. vol. 46, 2003, pages 3581-3599, XP002367530PATANI G.A. ET AL.: 'Bioisosterism: A rational approach in drug design' CHEM. REV. vol. 96, no. 8, 1996, pages 3147-3176, XP003003968PATHAK R. ET AL.: 'Effect of peroxisome proliferator-activated receptor-alpha agonist (bezafibrate) on gastric secretion and gastric cytoprotection in rats' FUNDAMENTAL & CLINICAL PHARMACOLOGY vol. 21, no. 3, 2007, pages 291-296, XP003023830 RUCKER C ET AL: "2D QSAR of PPARgamma agonist binding and transactivation", BIOORGANIC & MEDICINAL CHEMISTRY, PERGAMON, GB, vol. 14, no. 15, 1 August 2006 (2006-08-01), pages 5178-5195, XP025133414, ISSN: 0968-0896, DOI: 10.1016/J.BMC.2006.04.005 [retrieved on 2006-08-01]SZELES L. ET AL.: 'PPAR gamma in immunity and inflammation: cell types and diseases' BIOCHIMICA ET BIOPHYSICA ACTA vol. 1771, no. 8, 2007, pages 1014-1030, XP022189886[AGRAVE]GATHA CABRERO ET AL: 'Differential effects of peroxisome proliferator-activated receptor activators on the mrna levels of genes involved in lipid metabolism in primary human monocyte-derived macrophages' METABOLISM vol. 52, no. 5, 01 May 2003, pages 652-657, XP055033047 DOI: 10.1053/meta.2003.50100 ISSN: 0026-0495